CST11

Across TCGA pan-cancer cohorts, CST11 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CST11 data layer compared with 18 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CST11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CST11 expression acts as an unfavorable survival marker, although some lineages such as OV and LSCC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where CST11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.739	1.000	<.001	68	view →
PDAC	OS	Quartile	All	0.719	0.933	.009	23	view →
UCEC	OS	Tertile	III,IV	0.368	1.000	.027	8	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	5	view →
OV	DFS	Median	All	1.000	0.683	.049	4	view →
LSCC	DFS	Quartile	All	1.000	0.322	.006	3	view →
HNSC	DFS	Tertile	III,IV	0.671	0.853	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CST11–CCRCC (DFS)

Open the CCRCC breakdown →